says GlobalData
More research is required to determine whether current Omicron treatments are effective against BA.2—the most transmissible of the Omicron subvariants, says GlobalData. The leading data and analytics company notes that vaccines and therapies should be tested specifically against BA.2 to better prepare for challenges that may lay ahead. BA.2 contains numerous unique mutations compared to its predecessor that may allow it to circumvent immunization and treatment efforts. Leia Mais »